drugset
drugset / Trial / NCT04080804

Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer

NCT04080804 ↗

Phase 2 Active not recruiting 80 enrolled Dan Zandberg Bristol-Myers Squibb · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The aim of this study is to potentiate adaptive immunity to enhance the anti-tumor activity of anti-PD1 antibody by the addition of anti-CTLA4 antibody or anti-LAG3 antibody (relatlimab) given in subjects with resectable locally advanced HNSCC prior to surgical resection.

Timeline

Start
2019-12-20
Primary completion
2027-10-01
Completion
2027-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Ipilimumab Monoclonal antibody 1 mg/kg Intravenous
Subject Nivolumab Monoclonal antibody 3 mg/kg Intravenous
Subject Nivolumab Monoclonal antibody 480 mg Intravenous
Subject Relatlimab Monoclonal antibody 480 mg Intravenous

Indications

head and neck squamous cell carcinoma